NASDAQ$SGHT
Sight Sciences Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
Sight Sciences reported Q3 2025, revenue of $19.9M, net loss of $8.2M.
For Q3 2025, Sight Sciences reported revenue of $19.9M, a net loss of $8.2M. Management discusses segment performance, capital allocation, and outlook in the earnings filing.
- Revenue $19.9M.
- Net loss $8.2M.
- Sight Sciences highlights liquidity, operations, and near-term priorities.
Headline financials
Revenue & EPS history
Sight Sciences · Revenue · Quarterly
$19.9M
Revenue by segment
Sight Sciences · $20M total across 2 segments · Q3 2023
- Interventional Glaucoma$18.4M+7.6%92.0%
- Interventional Dry Eye$1.6M+0.0%8.0%
Forward guidance
The filing discusses Sight Sciences's outlook for upcoming periods, including capital allocation, operating priorities, and market risks disclosed in the quarterly report.
Tailwinds
- Sight Sciences cites operational execution and demand trends supporting the outlook.
- Balance sheet and liquidity actions aim to fund growth and returns.
- Procedure volumes and new product adoption support the revenue outlook.
Headwinds
- GAAP profitability remained under pressure in Q3 2025.
- Macro, pricing, and input-cost volatility could pressure margins.
- Segment mix and one-time items may affect quarter-to-quarter comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2025
+3.0%
Avg return
Earnings day
+4.0%
Avg return
5 days after
+5.0%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+60.9%
Q3 2022
Best reaction
-26.9%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.7% | +22.6% | +2.5% | |
| Q4 2025 | -26.9% | -25.9% | -34.9% | |
| Q3 2025 | +16.0% | +54.4% | +61.0% | |
| Q1 2025 | +1.3% | +8.3% | +38.6% | |
| Q4 2024 | +2.9% | +15.3% | -5.0% | |
| Q3 2024 | -17.1% | -17.1% | -24.1% | |
| Q2 2024 | -18.9% | -29.4% | -13.0% | |
| Q1 2024 | +6.6% | +1.1% | +17.4% | |
| Q4 2023 | +6.8% | -4.4% | +21.4% | |
| Q3 2023 | +19.8% | +2.0% | +54.1% | |
| Q2 2023 | +11.0% | +4.1% | -16.0% | |
| Q1 2023 | -0.4% | +0.6% | -25.1% | |
| Q4 2022 | +4.9% | -2.3% | -5.8% | |
| Q3 2022 | +60.9% | +50.4% | +72.9% | |
| Q2 2022 | -3.9% | -16.1% | -26.2% | |
| Q1 2022 | +11.2% | +23.9% | +59.2% | |
| Q4 2021 | -10.1% | -6.1% | -45.5% | |
| Q3 2021 | -2.4% | -5.8% | -20.6% | |
| Q2 2021 | -4.7% | +0.1% | -15.9% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro